Researchers from the IIBB-CSIC and the IDIBAPS publish an article in the journal Redox Biology in which they propose an alternative treatment for Niemann-Pick disease type C, a rare lysosomal pathology that causes neurodegeneration and impaired liver function. With a compound that crosses the blood-brain barrier, it is possible to increase the survival of the mice by 50% and to improve the neurological and motor problems related to the disease. Dr. José C. Fernández-Checa, head of the IDIBAPS team on Mitochondrial regulation of cell death and steatohepatitis, and Dr. Carmen García-Ruiz, from the same team, are the coordinators of the study, which has been carried out in collaboration with researchers from France and Chile. The first author of the study is Sandra Torres, predoctoral researcher in Dr. Fernández-Checa’s lab.
A treatment increases survival by 50% in mice with Niemann-Pick type C, a rare disease that affects brain and liver
A diagnostic test for lung cancer detects genetic alterations which may remain hidden when conventional techniques are used
A study led by researchers from Hospital Clínic-IDIBAPS, in collaboration with Dexeus University Hospital, shows the effectiveness of a new genetic test for molecular diagnosis in lung cancer. This is the first time that a test for this type of tumor is implemented in clinical practice. It consists of analyzing three genes with an innovative genomic technology that allows detecting multiple alterations which may not be identified when conventional diagnostic techniques are used. If these genetic alterations are detected, the patient can be treated with an oral drug that has minimal toxicity and a very high clinical benefit. The study has been coordinated by Dr. Noemí Reguart, an oncologist at the Hospital Clínic-IDIBAPS, and Dr. Aleix Prat, head of the Clinical Oncology Department and of the IDIBAPS research team on Translational Genomics and directed therapies in solid tumors.
Researchers discover a protein that protects against fatty liver, the most common hepatic disease in Western countries
A team co-headed by scientists at the Institute for Research in Biomedicine (IRB Barcelona) and the IDIBAPS Biomedical Research Institute (part of the Hospital Clínic de Barcelona) has revealed the capacity of the CPEB4 protein to prevent fatty liver disease. This condition generally leads to chronic inflammation (non-alcoholic steatohepatitis), which can trigger fibrosis, cirrhosis and ultimately liver cancer. This study on the basic biology of the liver paves the way to examine therapeutic strategies to fight and prevent fatty liver disease. The results have appeared in Nature Cell Biology this week.
Hospital Clinic-IDIBAPS leads a European project to fight against cirrhosis within the Horizon 2020 program
Hospital Clínic-IDIBAPS is leading a European project to evaluate the efficacy of treatment with the combination of rifaximin, an antibiotic that modulates the intestinal microbiome, and statins in patients with advanced cirrhosis. The project, called LIVERHOPE, will also focuse on the search for biomarkers of the disease. LIVERHOPE is coordinated by Dr. Pere Ginès, head of the Hepatology Department of the Hospital Clínic and of the team of Mechanisms of liver diseases and complications of cirrhosis of IDIBAPS, and a total of 16 institutions are participating among clinical centers, universities and European companies. This project is part of the Horizon 2020 European research and innovation framework program and it is endowed with a budget of 6 million euros.
Transplant Biomedical, one of the two spin-offs arising from IDIBAPS, will receive a maximum of 2.5 million euros to carry out the clinical phase of a medical device intended to improve the preservation and transport of kidneys and livers for transplantation. This economic injection is the result of an agreement with Caixa Capital Risc and Kereon Partners, the company founded, among others, by Carmen Peralta, coordinator of the group Strategies for the protection of hepatic injury induced by ischemia-reperfusion. Read the rest of this entry »
IDIBAPS researchers have participated in a study that shows how a new experimental drug could curb a wide variety of autoimmune diseases such as asthma, psoriasis, Crohn’s disease or multiple sclerosis without blocking the body’s natural response against infections caused by pathogens.